Vanuatu Health Times: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vanuatu Health Times.

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Press releases published on December 15, 2025

December 15, 2025

BioSyent Announces Renewal of Normal Course Issuer Bid

GlobeNewswire

December 15, 2025

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

December 15, 2025

Abivax Presents Third Quarter 2025 Financial Results

GlobeNewswire

December 15, 2025

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

GlobeNewswire

December 15, 2025

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

GlobeNewswire

$AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers$

December 15, 2025

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

GlobeNewswire

$AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers$

December 15, 2025

AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers

GlobeNewswire

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

December 15, 2025

U.S. Court of Appeals Affirms Novarad’s ’807 Patent as Company Continues to Defend Leadership in Augmented Reality Surgical Navigation

GlobeNewswire

December 15, 2025

New research in ONCOLOGY® identifies gaps between gynecologic cancer disease burden and clinical trial availability at UCLA Jonsson Comprehensive Cancer Center

GlobeNewswire

December 15, 2025

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

GlobeNewswire

December 15, 2025

TRIMEDX launches TRIMEDX-AIQ™, an AI-native clinical asset intelligence offering built on the industry’s most extensive repository of medical device data

GlobeNewswire

December 15, 2025

Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™

GlobeNewswire

December 15, 2025

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

GlobeNewswire

December 15, 2025

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

GlobeNewswire

December 15, 2025

BetaGlue Therapeutics erhält Genehmigung des belgischen Gesundheitsministeriums für klinische Studie mit YntraDose bei inoperablem lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (uLA-PDAC)

GlobeNewswire

December 15, 2025

BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)

GlobeNewswire

December 15, 2025

NeOnc Technologies Reports Updated Clinical Results

GlobeNewswire

Vanuatu Health Times: Press Releases

October 2025

November 2025

December 2025

Press releases published on December 15, 2025

BioSyent Announces Renewal of Normal Course Issuer Bid

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abivax Presents Third Quarter 2025 Financial Results

AEON Biopharma Announces Execution of Exchange Agreement with Daewoong

Monte Rosa Therapeutics to Present Updated MRT-2359 Phase 1/2 Study Results

AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers

AB Science annonce une nouvelle publication sur biorxiv identifiant AB8939 comme un candidat médicament prometteur pour le traitement de la leucémie myéloïde aiguë réfractaire et potentiellement d'autres cancers

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques

Booking Health Releases 2026 Rankings of Germany’s Most Trusted Cancer Hospitals for International Patients

U.S. Court of Appeals Affirms Novarad’s ’807 Patent as Company Continues to Defend Leadership in Augmented Reality Surgical Navigation

New research in ONCOLOGY® identifies gaps between gynecologic cancer disease burden and clinical trial availability at UCLA Jonsson Comprehensive Cancer Center

Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer

TRIMEDX launches TRIMEDX-AIQ™, an AI-native clinical asset intelligence offering built on the industry’s most extensive repository of medical device data

Global Gene Therapy Market to Surge to USD 36.55 Billion by 2032 | MarketsandMarkets™

Trinity Biotech Expands Global Rollout of High-Capacity Column System for FDA-Cleared HbA1c Testing Solution After Securing Regulatory Clearances

BetaGlue Therapeutics Receives Belgium Ministry of Health Approval for YntraDose Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)

BetaGlue Therapeutics erhält Genehmigung des belgischen Gesundheitsministeriums für klinische Studie mit YntraDose bei inoperablem lokal fortgeschrittenem Bauchspeicheldrüsenkrebs (uLA-PDAC)

BetaGlue Therapeutics obtient l’autorisation du ministère de la Santé belge pour mener un essai clinique portant sur YntraDose dans le traitement du cancer du pancréas localement avancé non résécable (uLA-PDAC)

NeOnc Technologies Reports Updated Clinical Results